Apellis Pharmaceuticals Enters Material Definitive Agreement
Ticker: APLS · Form: 8-K · Filed: Jul 1, 2025 · CIK: 1492422
Sentiment: neutral
Topics: material-definitive-agreement
Related Tickers: APLS
TL;DR
APLS signed a big deal, details TBD.
AI Summary
On July 1, 2025, Apellis Pharmaceuticals, Inc. entered into a material definitive agreement. The filing does not disclose the specific nature or terms of this agreement, only that it is a significant event requiring immediate reporting.
Why It Matters
This filing indicates a significant new development for Apellis Pharmaceuticals, potentially impacting its business operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement, warranting a medium risk assessment.
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — Registrant
- July 1, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Apellis Pharmaceuticals?
The filing does not specify the nature of the material definitive agreement.
When did Apellis Pharmaceuticals enter into this material definitive agreement?
Apellis Pharmaceuticals entered into the material definitive agreement on July 1, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 100 Fifth Avenue, Waltham, MA 02451.
What is the telephone number for Apellis Pharmaceuticals?
The telephone number for Apellis Pharmaceuticals is (617) 977-5700.
What is the Standard Industrial Classification code for Apellis Pharmaceuticals?
The Standard Industrial Classification code for Apellis Pharmaceuticals is 2834 (PHARMACEUTICAL PREPARATIONS).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 1, 2025 regarding Apellis Pharmaceuticals, Inc. (APLS).